Jeremy D. Waight, Ph.D.
Affiliations: | 2012 | Microbiology and Immunology | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Immunology, Molecular Biology, OncologyGoogle:
"Jeremy Waight"Parents
Sign in to add mentor| Scott I. Abrams | grad student | 2012 | SUNY Buffalo | |
| (Molecular mechanisms of tumor-induced myeloid-derived suppressor cell development.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Worboys JD, Vowell KN, Hare RK, et al. (2023) TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. Nature Communications. 14: 5016 |
| Yadavilli S, Waight JD, Brett S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer Research Communications. 3: 1564-1579 |
| Alsaid H, Cheng SH, Bi M, et al. (2022) Immuno-PET Monitoring of CD8 T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a Zr Anti-CD8 Mouse Minibody in EMT6 Syngeneic Tumor Mouse. Molecular Imaging and Biology |
| Dubuisson A, Fahrner JE, Goubet AG, et al. (2020) Immunodynamics of explanted human tumors for immuno-oncology. Embo Molecular Medicine. e12850 |
| Waight JD, Bi M, Kilian D, et al. (2020) Abstract 2220: Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies Immunology |
| Waight J, Manrique M, Gombos R, et al. (2019) Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies. Journal of Clinical Oncology. 37: e14126-e14126 |
| Chand D, Waight JD, Paltrinieri E, et al. (2019) Abstract 2390: FcgR co-engagement by anti-TIGIT monoclonal antibodies enhances T cell functionality and antitumor immune responses Cancer Research. 79: 2390-2390 |
| Waight JD, Chand D, Savitsky DA. (2018) New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy. Oncotarget. 9: 31171-31172 |
| Waight JD, Chand D, Dietrich S, et al. (2018) Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Cancer Cell. 33: 1033-1047.e5 |
| Gombos RB, Gonzalez A, Manrique M, et al. (2018) Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. Plos One. 13: e0191926 |